Bibliografía del artículo
1. Strebel PM, Sutter RW, Cochi SL y col. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus associated disease. Clin Infect Dis 14:568-79.
2. Kew OM, Sutter RW, De Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived PVes and the endgame strategy for global polio eradication. Annu Rev Microbiol 59:587-635, 2005.
3. Henderson RH. The World Health Organization's plan of action for global eradication of poliomyelitis by the year 2000. Ann NY Acad Sci 569:69-85, 1989.
4. Laboratory support for poliomyelitis eradication: Memorandum from a WHO meeting. Bull World Health Organ 67:365-7, 1989.
5. WHO/MNH/EPI. Acute onset flaccid paralysis.93.3.
6. Erradicación de la poliomielitis: Informe de la 1ª reunión de la Comisión regional Europea de certificación de la erradicación de la poliomielitis, París, 7-8 de marzo 1996.
7. Ministerio de Sanidad y Consumo. Plan de actuaciones necesarias para la consecución del certificado de erradicación de la poliomielitis. Junio 1997.
8. Avellón A, Trallero G, Merino B, Pachón I, Sanz C, Pérez-Breña P, Coordinadores Autonómicos responsables del Plan de Contención de PV salvaje en los laboratorios españoles. Erradicación de la poliomielitis. Búsqueda y control de PV salvajes almacenados en los laboratorios españoles. Enferm Infecc Microbiol Clin 22(2):77-82, 2004.
9. WHO. Poliomielitis outbreak escalates in the Sudan. Wkly Epidemilol Rec 80:2-3, 2005.
10. Cent. Dis. Control Prevent Certification of poliomielitis eradication- the Americas, 1994. Morbid Mortal Wkly Rep 43:720-22, 1994.
11. Cent. Dis. Control Prevent. Certification of poliomielitis eradication- Western Pacific Region, October 2000. Morbid Mortal Wkly Rep 50.1-3, 2001.
12. Cent. Dis. Control Prevent. Certification of poliomielitis eradication- European Region, June 2002. Morbid Mortal Wkly Rep 51:572-574, 2002.
13. WHO. Transmisión of wild PV type 2: apparent global interruption. Wkly Epidemilol Rec 76:95-97, 2001.
14. Trallero G, Avellón A, Otero A y col. Laboratory Network within the Polio Eradication Initiative (1998-2003): six years of surveillance for acute flaccid paralysis in Spain. Enferm Infecc Microbiol Clin 24(3):167-72, 2006.
15. Ministerio de Sanidad y Consumo. Plan de actuaciones necesarias para la consecución del certificado de erradicación de la poliomielitis. Versión noviembre 1998.
16. Melnick JL,Wimberly IL. Lyophilised combination pools of EV equine antiserum New LBM pools prepared from reserves of antiserum stored frozen for two decades. Bull WHO 63:543-550, 1985.
17. Casas I, Palacios GF, Trallero G, Cisterna D, Freire MC, Tenorio A. Molecular characterization of human EVes in clinical samples: comparison between VP2, VP1, and RNA polymerase regions using RT nested PCR assays and direct sequencing of products. J Med Virol 65(1):138-48, 2001.
18. Yang CF, De L, Holloway BP, Pallansch MA, Kew OM. Detection and identification of vaccine-related PVes by the polymerase chain reaction. Virus Res 20(2):159-79, 1991.
19. Kew O, Morris-Glasgow V, Landaverde M y col. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived PV. Science 296(5566):356-9, 2002.
20. Avellón A, Cabrerizo M, De Miguel T y col. Paralysis case and contact spreading of an imported recombinant vaccine-derived PV in Spain. Emerging Infectious Diseases, submitted.
21. Trallero G, Casas I, Tenorio A, Echevarría JE, Castellanos A, Lozano A, Brena PP. EVes in Spain: virological and epidemiological studies over 10 years (1988-97). Epidemiol Infect 124(3):497-506, 2000.
22. Aylward RB, Hull HF, Cochi SL, Sutter RW, Olive JM, Melgaard B. Disease eradication as a public health strategy: a case study of poliomyelitis eradication. Bull World Health Organ 78(3):285-97, 2000.
23. Agol VI, Chumakov K, Ehrenfeld E and Wimmer E. Don't drop current vaccine until we have new ones. Nature 435:881, 2005.
24. Dowdle WR, De Gourville E, Kew OM, Pallansch MA, Wood DJ. Polio eradication: the VPO paradox. Rev Med Virol 13:277-91, 2003.
25. Mueller S, Papamichail D, Coleman JR, Skiena S, Wimmer E. Reduction of the rate of PV protein synthesis through large-scale codon deoptimization causes attenuation of viral virulence by lowering specific infectivity. J Virol 80:9687-96, 2006.
26. Macadam AJ, Ferguson G, Stone DM, et al. Rational design of genetically stable, live-attenuated PV vaccines of all three serotypes: relevance to poliomyelitis eradication. J Virol 80:8653-63, 2006.
27. Vignuzzi M, Wendt E, Andino R. Engineering attenuated virus vaccines by controlling replication fidelity. Nat Med 14:154-61, 2008.
28. World Health Organization proposed global action plan and timetable for safe handing and maximun laboratory containment of wild PVes and potentially infectious materials, 1998.
29. Dowdle WR, Wolff C, Sanders R, Lambert S, Best M. Will containment of wild PV in laboratories and inactivated PV vaccine production sites be effective for global certification? Bull World Health Organ 82(1):59-62, 2004.